Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis

ConclusionsCombined activity of the ER and BRAF/MEK pathways may represent a novel biomarker for CRC prognosis and clinical management.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research